Table 1.

Characteristics of studies included in the analysis

Study number	Study	Number of patiens	Gender (male/female)	Median (range) age (years)	Tumour type	Study phase	Drugs	The baseline for including AEs
1	Kurzrock et al., 2008 14	35	23/12	48.3 (18–74)	Advanced solid tumours	I	R1507	All
2	Tolcher et al., 2009 29	53	38/15	54 (22–84)	Refractory solid tumours	I	Ganitumab	All
3	Naing et al., 2011 30	42	19/23	53 (20–79)	Advanced cancer	I	CIX and Torisel	All
4	Molife et al., 2010 25	46	40/6	59.4 (25–79)	Advanced solid tumours	Ib	CP and DOC	All figitumumab related
5	Karp et al., 2009 22	42	24/18	60.5 (26–80)	Advanced cancer	Ib	CP and PAC and CB	>5% figitumumab related
6	Olmos et al., 2010 27	29	21/8	30 (12–63)	Sarcoma and Ewing's sarcoma	I	CP	All
7	Atzori et al., 2011 31	80	40/40	57 (19–81)	Advanced solid tumours	I	Dalotuzumab	All
8	Weickhardt et al., 2012 9	18	8/10	65 (48–77)	Advanced NSCLC	I/II	CIX and erlotinib	≥10%, or ≥grade 3
9	Quek et al., 2010 32	21	12/9	56 (25–77)	Advanced sarcomas and other solid tumours	I	CP and everolimus	≥10%
10	Goto et al., 2011 33	19	12/7	57 (21–74)	Advanced NSCLC	I	CP,CB and PAC	All
11	Malempati et al., 2011 34	47	24/23	15 (4–28)	Paediatric patients with refractory solid tumours and Ewing sarcoma	I/II	CIX	≥Grade 2
12	Pappo et al., 2011 4	115	75/40	25 (8–78)	Recurrent or refractory Ewing sarcoma	II	R1507	≥5%
13	Ramalingam et al., 2011 11	114	77/37	62.5	Advanced NSCLC	II	Erlotinib with placebo or R1507	All
14	Reidy et al., 2010 10	64	33/31	61 (40–84)	Refractory metastatic colorectal cancer	II	CIX, with or without cetuximab	≥Grade 2
15	Lacy et al., 2008 35	47	30/17	61.3 (42–81)	Multiple myeloma	I	CP	≥4%
Total:		772	476/296	50 (4–84)		I/II

^*QW:once a week, Q3W:once every three weeks. CIX, cixutumumab; CP, figitumumab; DOC, docetaxel; NSCLC, non-small cell lung cancer; PAC, paclitaxel; CB, carboplatin; Torisel, temsirolimus.